Literature DB >> 27734581

Mechanistic target of rapamycin modulation: an emerging therapeutic approach in a wide variety of disease processes.

Albert Ferro1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27734581      PMCID： PMC5061785          DOI： 10.1111/bcp.13117

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  12 in total

Review 1.  The therapeutic potential of mTOR inhibitors in breast cancer.

Authors:  Linda S Steelman; Alberto M Martelli; Lucio Cocco; Massimo Libra; Ferdinando Nicoletti; Stephen L Abrams; James A McCubrey
Journal:  Br J Clin Pharmacol       Date:  2016-05-10       Impact factor: 4.335

2.  RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs.

Authors:  D M Sabatini; H Erdjument-Bromage; M Lui; P Tempst; S H Snyder
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

3.  Mechanistic target of rapamycin modulation: an emerging therapeutic approach in a wide variety of disease processes.

Authors:  Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2016-11       Impact factor: 4.335

Review 4.  New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease.

Authors:  Mathias Lutz; Stephan Mielke
Journal:  Br J Clin Pharmacol       Date:  2016-06-22       Impact factor: 4.335

Review 5.  New perspectives on the involvement of mTOR in depression as well as in the action of antidepressant drugs.

Authors:  Zuleide M Ignácio; Gislaine Z Réus; Camila O Arent; Helena M Abelaira; Meagan R Pitcher; João Quevedo
Journal:  Br J Clin Pharmacol       Date:  2016-01-08       Impact factor: 4.335

Review 6.  Targeting mTOR for the treatment of B cell malignancies.

Authors:  Jong-Hoon Scott Lee; Thanh-Trang Vo; David A Fruman
Journal:  Br J Clin Pharmacol       Date:  2016-03-03       Impact factor: 4.335

Review 7.  Therapeutic potential of mTOR inhibitors for targeting cancer stem cells.

Authors:  Maria Giovanna Francipane; Eric Lagasse
Journal:  Br J Clin Pharmacol       Date:  2015-12-26       Impact factor: 4.335

Review 8.  New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.

Authors:  Matthias Waldner; Daniel Fantus; Mario Solari; Angus W Thomson
Journal:  Br J Clin Pharmacol       Date:  2016-03-06       Impact factor: 4.335

9.  A mammalian protein targeted by G1-arresting rapamycin-receptor complex.

Authors:  E J Brown; M W Albers; T B Shin; K Ichikawa; C T Keith; W S Lane; S L Schreiber
Journal:  Nature       Date:  1994-06-30       Impact factor: 49.962

Review 10.  Potential therapeutic effects of mTOR inhibition in atherosclerosis.

Authors:  Ammar Kurdi; Guido R Y De Meyer; Wim Martinet
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335
View more
  3 in total

1.  Mechanistic target of rapamycin modulation: an emerging therapeutic approach in a wide variety of disease processes.

Authors:  Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2016-11       Impact factor: 4.335

Review 2.  Harnessing the Power of SIRT1 and Non-coding RNAs in Vascular Disease.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2017       Impact factor: 1.990

3.  Reply to 'Comment on 'Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomised controlled VaSera trial' by Faconti et al.'

Authors:  Luca Faconti; J Kennedy Cruickshank; Andrew James Webb
Journal:  Br J Clin Pharmacol       Date:  2019-03-04       Impact factor: 4.335
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.